Vectura develops inhaled therapies principally for the treatment of respiratory diseases. Inhaled formulation development is increasingly complex with a wide variety of small molecules and biologics, increasing use of combination products and the need for targeted lung delivery or deep lung deposition
for systemic delivery. We offer formulation services for DPI, pMDI and nebuliser development,
including small molecules and biologics, complex combinations and generic products.